Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain
Study Identifier
M06-850
CT.gov Identifier
EudraCT Identifier
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Study Details
Medical Condition
Study Drug
Phase
Phase 2
Sex
Female & Male
Age
18 - 75 Years
Protocol Summary
This study will compare the efficacy and the safety of ABT-894 (1mg, 2mg or 4mg capsules) administered BID to placebo in the treatment of DNP. Another treatment arm will be Duloxetine 60mg administered once daily (QD). Approximately 275 subjects will be enrolled into the study at approximately 50 sites in both the United States and Europe. The study will be divided into the following periods: Screening/Washout (21 days) followed by a Baseline Visit, an 8-week Treatment Period and a 1-week Follow-up Visit.
Study Locations
Location
Status
Location
Site Reference ID/Investigator# 5207
Mesa, Arizona, United States, 85210
Status
Not applicable
Location
Site Reference ID/Investigator# 6053
Phoenix, Arizona, United States, 85023
Status
Not applicable
Location
Site Reference ID/Investigator# 5206
Little Rock, Arkansas, United States, 72205
Status
Not applicable
Location
Site Reference ID/Investigator# 7387
North Little Rock, Arkansas, United States, 72114
Status
Not applicable
Location
Site Reference ID/Investigator# 6052
Anaheim, California, United States, 92801
Status
Not applicable
Location
Site Reference ID/Investigator# 7064
Garden Grove, California, United States, 92845
Status
Not applicable
Showing {first} - {last} of {total} Results